OTC: SGMO
SANGAMO THERAPEUTICS, INCCIK 0001001233 · SIC 2836 · Biological Products
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (IREN 10-K) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade SGMO commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed May 14, 2026 (period ending Mar 31, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Consolidated Statements of Operations (Unaudited)
(Unaudited; in thousands, except per share amounts)
| Description | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Revenues | 1,442 | 6,437 |
| Operating expenses: | ||
| Research and development | 26,570 | 26,006 |
| General and administrative | 6,818 | 10,059 |
| Total operating expenses | 33,388 | 36,065 |
| Loss from operations | (31,946) | (29,628) |
| Interest income | 300 | 309 |
| Other income (expense), net | 651 | (1,159) |
| Loss before income taxes | (30,995) | (30,478) |
| Income tax expense | — | 119 |
| Net loss | (30,995) | (30,597) |
| Basic and diluted net loss per share | (0.08) | (0.14) |
| Shares used in computing basic and diluted net loss per share | 389,616 | 220,269 |
Condensed Consolidated Balance Sheets (Unaudited)
(Unaudited; in thousands)
| Description | March 31, 2026 | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | 27,586 | 20,948 |
| Accounts receivable | 873 | 371 |
| Refundable research income tax credits | 5,491 | 10,142 |
| Prepaid expenses and other current assets | 3,164 | 4,369 |
| Total current assets | 37,114 | 35,830 |
| Property and equipment, net | 10,317 | 11,042 |
| Operating lease right-of-use assets | 2,905 | 3,064 |
| Refundable research income tax credits, non-current | 8,759 | 8,938 |
| Other non-current assets | 870 | 871 |
| Total assets | 59,965 | 59,745 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||
| Current liabilities: | ||
| Accounts payable | 19,307 | 14,437 |
| Accrued compensation and employee benefits | 18,341 | 17,721 |
| Other accrued liabilities | 15,084 | 9,409 |
| Deferred revenues | 402 | 899 |
| Total current liabilities | 53,134 | 42,466 |
| Deferred revenues, non-current | 5,874 | 5,874 |
| Long-term portion of lease liabilities | 19,332 | 25,093 |
| Other non-current liabilities | 580 | 580 |
| Total liabilities | 78,920 | 74,013 |
| Commitments and contingencies | ||
| Stockholders’ deficit: | ||
| Preferred stock | — | — |
| Common stock | 4,143 | 3,507 |
| Additional paid-in capital | 1,637,659 | 1,610,938 |
| Accumulated deficit | (1,658,244) | (1,627,249) |
| Accumulated other comprehensive loss | (2,513) | (1,464) |
| Total stockholders’ deficit | (18,955) | (14,268) |
| Total liabilities and stockholders’ deficit | 59,965 | 59,745 |
Condensed Consolidated Statements of Cash Flows (Unaudited)
(Unaudited; in thousands)
| Description | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Operating Activities: | ||
| Net loss | (30,995) | (30,597) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 719 | 1,020 |
| Amortization in operating lease right-of-use assets | 158 | 904 |
| Stock-based compensation | 992 | 2,596 |
| Deferred income tax benefit | — | 15 |
| Other | — | (10) |
| Net changes in operating assets and liabilities: | ||
| Accounts receivable | (502) | 160 |
| Prepaid expenses and other assets | 1,201 | (2,631) |
| Refundable research income tax credits | 4,525 | — |
| Accounts payable and other accrued liabilities | 4,936 | 4,216 |
| Accrued compensation and employee benefits | 630 | (591) |
| Lease liabilities | (449) | (1,231) |
| Deferred revenues | (497) | — |
| Net cash used in operating activities | (19,282) | (26,149) |
| Investing Activities: | ||
| Purchases of property and equipment | (13) | — |
| Net cash used in investing activities | (13) | — |
| Financing Activities: | ||
| Proceeds from issuance of common stock, net of offering expenses | 23,346 | — |
| Proceeds from at-the-market offering, net of offering expenses | 3,732 | 10,361 |
| Taxes paid related to net share settlement of equity awards | (379) | (2,227) |
| Net cash provided by financing activities | 26,699 | 8,134 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | (766) | 1,277 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 6,638 | (16,738) |
| Cash, cash equivalents, and restricted cash, beginning of period | 20,948 | 43,418 |
| Cash, cash equivalents, and restricted cash, end of period | 27,586 | 26,680 |
| Supplemental cash flow disclosures: | ||
| Offering expenses in relation to issuance of common stock included in unpaid liabilities | 333 | — |
| Property and equipment included in unpaid liabilities | 55 | 234 |
| Offering expenses in relation to issuance of common stock in at-the-market offering included in unpaid liabilities | — | 165 |
Amounts as printed on the EDGAR/iXBRL face — (Unaudited; in thousands, except per share amounts); (Unaudited; in thousands). Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗